| Literature DB >> 25769794 |
Nina Shah1, Natalie Callander2, Siddhartha Ganguly3, Zartash Gul4, Mehdi Hamadani5, Luciano Costa6, Salyka Sengsayadeth7, Muneer Abidi8, Parameswaran Hari5, Mohamad Mohty9, Yi-Bin Chen10, John Koreth11, Heather Landau12, Hillard Lazarus13, Helen Leather14, Navneet Majhail15, Rajneesh Nath16, Keren Osman17, Miguel-Angel Perales12, Jeffrey Schriber18, Paul Shaughnessy19, David Vesole20, Ravi Vij21, John Wingard22, Sergio Giralt12, Bipin N Savani7.
Abstract
Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.Entities:
Keywords: Guidelines; Multiple myeloma; Recommendations; Transplantation
Mesh：
Substances：
Year: 2015 PMID： 25769794 DOI： 10.1016/j.bbmt.2015.03.002
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742